Double Jeopardy!

Co-presentation of anti GBM and anti MPO antibodies is considered to be a rare phenomena. When patients present both types of antibodies, the condition is referred to as “double positive” for anti-GBM and ANCA associated antibodies which can present clinically as rapidly progressive glomerulonephritis [RPGN], often associated with alveolar bleeding and renal manifestations which constitutes a medical emergency associated with increased morbidity and mortality. In current clinical practice, the diagnosis is obtained through serological tests that detect the presence of antibodies and kidney biopsy to identify their specific histopathological changes. We highlight the role of clinical Biochemistry laboratory and specifically LIA technique in playing a crucial role in identifying the disease thus providing timely intervention to aid better patient outcome.